2021
Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome
Quraishi IH, Szekely AM, Shirali AC, Mistry PK, Hirsch LJ. Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome. Neurology Genetics 2021, 7: e614. PMID: 34337151, PMCID: PMC8320328, DOI: 10.1212/nxg.0000000000000614.Peer-Reviewed Original ResearchAction myoclonus-renal failure syndromeNeurologic symptomsAction myoclonusFailure syndromeProgressive myoclonic epilepsySubstrate reduction therapyWhole-exome sequencingMiglustat therapyAvailable medicationsEarly mortalityReduction therapyMyoclonic epilepsySteady worseningGaucher diseaseMyoclonusGlycosphingolipid metabolismExome sequencingGene mutationsGlucosylceramide accumulationPatientsSeizuresMiglustatSyndromeTherapySymptoms
2016
Effective Treatment of Paroxysmal Nonkinesigenic Dyskinesia With Oxcarbazepine
Kumar A, Szekely A, Jabbari B. Effective Treatment of Paroxysmal Nonkinesigenic Dyskinesia With Oxcarbazepine. Clinical Neuropharmacology 2016, 39: 201-205. PMID: 27046658, DOI: 10.1097/wnf.0000000000000149.Peer-Reviewed Original ResearchConceptsParoxysmal nonkinesigenic dyskinesiaRare chronic disorderOutcome of treatmentSeverity of episodesAvailable therapiesChronic disordersClinical trialsInvoluntary movementsEffective treatmentOxcarbazepinePharmaceutical agentsDyskinesiaPatientsTreatmentDisordersTherapyDebilitatingDiseaseTrialsSeverity